Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 12:11 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 12,649 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Period A Clear all

Conditions: Healthy
Interventions: Acoramidis; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Primary Sclerosing Cholangitis
Interventions: Vidofludimus calcium; Drug
Lead sponsor: Elizabeth Carey; Other
Eligibility: 18 Years to 75 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 3
States / cities: Phoenix, Arizona • Tempe, Arizona • Rochester, Minnesota

Conditions: Minimal Residual Disease, KRAS G12D, KRAS G12R, NRAS G12D, NRAS G12R, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Non-small Cell Lung Cancer, Ovarian Cancer, Cholangiocarcinoma, Bile Duct Cancer, Gallbladder Carcinoma
Interventions: ELI-002 2P; Drug
Lead sponsor: Elicio Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 10
States / cities: Duarte, California • Los Angeles, California • Aurora, Colorado + 7 more

Conditions: Opioid-use Disorder
Interventions: XR-B (SUBLOCADETM), XR-NTX; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 675 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 6
States / cities: New Haven, Connecticut • Baltimore, Maryland • Hanover, New Hampshire + 3 more

Conditions: ESRD, Extracellular Fluid Alteration, Hypertension
Interventions: Intradialytic Blood Pressure Slope Based Ultrafiltration; Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Back Pain, Intervertebral Disc Degeneration
Interventions: Physical Therapy; Procedure
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 30 Years to 70 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Heart Failure With Preserved Ejection Fraction, Pulmonary Disease, Left Ventricular Hypertrophy/Hypertension
Interventions: Dobutamine, Amlodipine; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Blastoid Variant Mantle Cell Lymphoma, Mantle Cell Lymphoma, Pleomorphic Variant Mantle Cell Lymphoma
Interventions: Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin, Doxorubicin Hydrochloride, Ibrutinib, Laboratory Biomarker Analysis, Methotrexate, Rituximab, Vincristine, Vincristine Sulfate; Drug · Other · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cardiovascular Diseases, Diabetes Mellitus, Type 2, Depression, Dysthymic Disorder
Interventions: Motivational Interviewing/Cognitive Behavioral-based Therapy; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Metastatic Melanoma, Skin Cancer
Interventions: Ipilimumab, Nivolumab, Cryoablation; Drug · Procedure
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Type2 Diabetes
Interventions: Emotion-Focused CBT; Behavioral
Lead sponsor: University of Chicago; Other
Eligibility: 21 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Sleep Disorders, Circadian Rhythm, Insomnia, Psychomotor Agitation
Interventions: risperidone; Drug
Lead sponsor: Child Psychopharmacology Institute; Other
Eligibility: 2 Years to 10 Years · Female only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Resident Communication Skills Rated by Patients
Interventions: Communication Skills Curriculum; Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 411 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Lung Cancer Stage III, Lung Cancer Stage IV
Interventions: Self-System Therapy for Older Adults with Advanced Lung Cancer (SST-LC); Behavioral
Lead sponsor: Duke University; Other
Eligibility: 65 Years to 100 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Mild Cognitive Impairment (MCI), Mild Alzheimer Disease, Memory Deficits
Interventions: home-based self-administered interactive exercise; Device
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 50 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer
Interventions: D-0502; Drug
Lead sponsor: InventisBio Co., Ltd; Industry
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Acinetobacter Baumannii-calcoaceticus Complex Infections
Interventions: ETX2514, 14C-ETX2514; Drug
Lead sponsor: Entasis Therapeutics; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hypertension (HTN)
Interventions: Practice support And Community Engagement (PACE); Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Gastric Cancer
Interventions: Cisplatin, Capecitabine, Telatinib; Drug
Lead sponsor: ACT Biotech, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 5
States / cities: San Francisco, California • Macon, Georgia • Philadelphia, Pennsylvania + 2 more

Conditions: Healthy Volunteers
Interventions: Soticlestat; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: COPD
Interventions: GFF MDI (PT003) with Aerochamber, GFF MDI (PT003) without Aerochamber; Device
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 6
States / cities: Clearwater, Florida • Tampa, Florida • Winter Park, Florida + 3 more

Conditions: Parkinson Disease
Interventions: Varenicline, Sugar pill; Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: 40 Years to 90 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Type 1 Diabetes Mellitus
Interventions: Faster Insulin Aspart (Fiasp®); Drug
Lead sponsor: Mountain Diabetes and Endocrine Center; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Asheville, North Carolina

Conditions: Kidney Transplant, Overweight or Obese Adults, Glucose Control
Interventions: Standard medical care, Monitoring Contacts, Behavioral Sessions, Diet, Physical Activity; Other · Behavioral
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Kansas City, Kansas

Search by objective public record fields.

Study to Assess the Effect of Food on a Single Dose of Acoramidis in Healthy Adult Participants

Vidofludimus Calcium for Primary Sclerosing Cholangitis

A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors

Long-acting Buprenorphine vs. Naltrexone Opioid Treatments in CJS-involved Adults

Using Intradialytic Blood Pressure Slopes to Guide Ultrafiltration

The Role of Disc Nutrition in the Etiology and Clinical Treatment of Disc Degeneration

Reduced Contractile Reserve: a Therapeutic Target in Heart Failure With Preserved Ejection Fraction(HFpEF)

Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma

Motivational Interviewing and Cognitive Behavioral Therapy-based Intervention for Cardiovascular Disease Prevention Amongst American Indians With Diabetic and Depressive Symptoms

Cryoablation+Ipilimumab+Nivolumab in Melanoma

An Emotion-Focused Intervention for Glycemic Control in T2D

Actigraphic Analysis of Treatment Response

Measuring the Impact of an Interactive Communication Skills Curriculum on Internal Medicine Residents

Self-System Therapy for Older Adults With Lung Cancer

Self-Administered Interactive Exercise Program (Tele-Exergame)

Food Effect Study of D-0502 Tablet in Healthy Volunteers

Study to Determine the Excretion and Metabolism of 14C-ETX2514 Administered Intravenously in Healthy Male Subjects

Actions to Decrease Disparities in Risk and Engage in Shared Support for Blood Pressure Control (ADDRESS-BP) in Blacks

A Study of Telatinib in Combination With Chemotherapy in Subjects With Advanced Gastric Cancer

A Study of Soticlestat Tablets in Healthy Adults

Crossover Study to Assess the Efficacy of PT003 With and Without a Valved Holding Chamber in Subjects With Moderate to Severe COPD

Varenicline for Gait and Balance Impairment in Parkinson Disease

The Efficacy and Safety of Faster Insulin Aspart (Fiasp®) Compared to Conventional Insulin Aspart (NovoLog®) as Correction Bolus

Feasibility and Plausible Effectiveness of a Lifestyle Intervention in Kidney Transplant Recipients (HEAL)